GLP-1 Drugs & Thyroid Cancer Risk: What the Latest Research Shows

The growing use of medications like Ozempic, Wegovy, and Mounjaro – GLP-1 receptor agonists initially developed for type 2 diabetes – has sparked public concern about potential health risks. A recently released white paper from the Clayman Thyroid Center addresses one such concern: whether these drugs increase the risk of thyroid cancer. The comprehensive review, published in February 2026, offers reassuring findings for most patients, clarifying a complex issue often fueled by misunderstanding and preliminary data.

Understanding GLP-1 Receptor Agonists and the FDA Warning

GLP-1 receptor agonists work by mimicking a natural hormone that helps regulate blood sugar and promotes weight loss. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are two prominent examples. Yet, the Food and Drug Administration (FDA) includes a “boxed warning” – the most serious type of warning – on these medications. This warning doesn’t relate to the common forms of thyroid cancer, but to a rare type called medullary thyroid carcinoma (MTC). The warning also extends to individuals with Multiple Endocrine Neoplasia syndrome type 2 (MEN2), a genetic condition that predisposes people to MTC.

The FDA’s caution stems from studies conducted in rodents, where GLP-1 receptor agonists were shown to cause C-cell hyperplasia and tumors. C-cells are responsible for producing calcitonin, a hormone involved in calcium regulation. However, as the Clayman Thyroid Center’s white paper highlights, there are significant biological differences between rodents and humans. Human C-cells express substantially lower levels of GLP-1 receptors, and the cellular response to these medications differs. Crucially, human studies haven’t shown a clinically meaningful increase in calcitonin levels following GLP-1 receptor agonist use, suggesting the same C-cell stimulation observed in animals doesn’t occur in humans.

What the Evidence Shows: Human Studies and Registry Data

The Clayman Thyroid Center’s review examined several large-scale studies evaluating thyroid cancer risk in humans using GLP-1 receptor agonists. A Scandinavian cohort study, published in BMJ in 2024, analyzed data from national registers in Denmark, Norway, and Sweden. The study found no substantially increased risk of thyroid cancer among GLP-1 receptor agonist users over an average follow-up period of four years. Similarly, an international analysis published in Thyroid in 2025 demonstrated no evidence of increased risk across six population-based databases.

Researchers also analyzed data from the TriNetX electronic health record (EHR) database, comparing GLP-1 users to individuals taking other diabetes and weight management medications like insulin, metformin, and SGLT2 inhibitors. This propensity-matched study revealed no increased thyroid cancer risk compared to any of the comparator groups. While some reports to the FDA Adverse Event Reporting System (FAERS) suggested a possible link, the authors attribute this to increased awareness and reporting prompted by media coverage and the FDA warning itself, rather than a true increase in incidence.

The Role of Detection Bias and Thyroid Cancer Subtypes

The white paper addresses a critical factor that can skew study results: detection bias. Patients prescribed GLP-1 receptor agonists often undergo more frequent medical evaluations, including lab tests and imaging, due to their weight loss goals. Endocrinologists prescribing these medications may also routinely perform thyroid ultrasounds. This increased surveillance can lead to the discovery of pre-existing thyroid nodules and early-stage cancers that might otherwise have remained undetected. The authors note that a concentration of diagnoses shortly after starting the medication is inconsistent with the timeline for new cancer development, further supporting the idea of detection bias.

It’s also important to understand that “thyroid cancer” isn’t a single disease. Differentiated thyroid cancers – papillary thyroid carcinoma (PTC), follicular thyroid carcinoma (FTC), and Oncocytic (Hürthle cell) carcinoma – account for 95% to 97% of all cases. The FDA warning specifically applies to MTC, a much rarer subtype. The Clayman Thyroid Center, which treats approximately 2,000 thyroid cancer patients annually, has not observed a clinical association between GLP-1 exposure and the presentation of MTC.

Clinical Guidance and What This Means for Patients

The Clayman Thyroid Center’s review provides a framework for clinicians. GLP-1 receptor agonists remain contraindicated in patients with a personal or family history of MTC or MEN2. However, for individuals with a history of PTC, FTC, or Hürthle cell cancer, there is no contraindication to therapy. The decision to use these medications should be individualized, carefully weighing the potential metabolic and cardiovascular benefits against theoretical concerns.

The authors emphasize that GLP-1 therapy does not warrant additional thyroid imaging or calcitonin testing beyond standard clinical guidelines. The presence of common thyroid nodules is also not considered a reason to avoid starting therapy. This guidance is consistent with the broader understanding that the benefits of these medications often outweigh the risks for appropriate candidates.

What Comes Next: Ongoing Surveillance and Research

While current evidence is reassuring, ongoing surveillance and research are crucial. The Clayman Thyroid Center and other institutions continue to monitor thyroid cancer incidence among GLP-1 receptor agonist users. Further studies are needed to refine our understanding of the long-term effects of these medications and to identify any potential subgroups of individuals who may be at increased risk. Public health agencies, including the FDA, will continue to evaluate new data and update guidance as needed. Patients should discuss any concerns with their healthcare provider and stay informed about official updates from reputable sources like the Food and Drug Administration and the National Cancer Institute.

the available evidence suggests that the fear surrounding GLP-1 receptor agonists and thyroid cancer is largely driven by misunderstanding rather than strong scientific data. For the vast majority of patients, the benefits of these medications appear to outweigh the risks.